Viewing StudyNCT02521051



Ignite Creation Date: 2024-05-06 @ 7:22 AM
Last Modification Date: 2024-10-26 @ 11:47 AM
Study NCT ID: NCT02521051
Status: UNKNOWN
Last Update Posted: 2019-11-26
First Post: 2015-07-20

Brief Title: Phase III Trial of Alectinib and Bevacizumab in Patients With Advanced Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer
Sponsor: Massachusetts General Hospital
Organization: Massachusetts General Hospital

Conditions & Keywords Data

Conditions:
Name
Non-Small Cell Lung Cancer NSCLC
Keywords:
Name View
Brain metastases View
Non-Small Cell Lung Cancer NSCLC View
Anaplastic lymphoma kinase View
ALK View